Expression of HER-2/neu oncogene in hepatocellular carcinoma and the clinical implications.
- Author:
Jun-kai ZHANG
1
;
Pei-ling PAN
;
Ying-meng WU
;
Jian-jun XIAO
;
Jie-wen PENG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; genetics; metabolism; Female; Humans; Liver Neoplasms; genetics; metabolism; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; genetics; metabolism
- From: Journal of Southern Medical University 2010;30(2):326-328
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the expression of human epidermal growth factor receptor 2 (HER-2/neu) in hepatocellular carcinoma (HCC) patients and its clinical significance.
METHODSThe expressions of HER-2/neu were detected by SP immunohistochemistry method in 30 patients with HCC, 10 with portal cirrhosis of the liver and 10 with normal liver.
RESULTSThe positivity rate of HER-2/neu was markedly higher in HCC patients than in those with portal cirrhosis and normal liver (Chi(2)=6.482, P=0.032). The expression of HER-2/neu was closely correlated to portal cirrhosis of the liver (P=0.041), tumor invasion (P=0.028) and Edmondson grades (P=0.012). The average survival time was significant shorter in patients with HER-2/neu-positive tumor than in those with HER-2/neu-negative tumor (P=0.036).
CONCLUSIONThe expression of HER-2/neu may play a role in the invasion, metastasis and progression of HCC. The patients positive for HER-2/neu in the HCC tissues have generally poor prognosis.
